RECURSION PHARMACEUTICALS, INC. Payments for Restructuring
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Payments for Restructuring of $8.52 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2025-12-31 was $804.00K.
- RECURSION PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2025-09-30 was $3.81M.
- RECURSION PHARMACEUTICALS, INC. payments for restructuring for fiscal 2025 was $8.52M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2025-12-31 | $804.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.62M derived: sum of 2 quarters · filed 2026-02-25 | $8.52M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $3.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.72M 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $3.90M 10-Q · filed 2025-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |